Schlagbauer-Wadl H - Search Results

1

Chemosensitisation of malignant melanoma by BCL2 antisense therapy.

Jansen B, Wacheck V, Heere-Ress E, Schlagbauer-Wadl H, Hoeller C, Lucas T, Hoermann M, Hollenstein U, Wolff K, Pehamberger H. Jansen B, et al. Among authors: schlagbauer wadl h. Lancet. 2000 Nov 18;356(9243):1728-33. doi: 10.1016/S0140-6736(00)03207-4. Lancet. 2000. PMID: 11095261 Clinical Trial.

2

Bcl-X(L) is a chemoresistance factor in human melanoma cells that can be inhibited by antisense therapy.

Heere-Ress E, Thallinger C, Lucas T, Schlagbauer-Wadl H, Wacheck V, Monia BP, Wolff K, Pehamberger H, Jansen B. Heere-Ress E, et al. Among authors: schlagbauer wadl h. Int J Cancer. 2002 May 1;99(1):29-34. doi: 10.1002/ijc.10248. Int J Cancer. 2002. PMID: 11948488 Free article.

3

bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice.

Jansen B, Schlagbauer-Wadl H, Brown BD, Bryan RN, van Elsas A, Müller M, Wolff K, Eichler HG, Pehamberger H. Jansen B, et al. Nat Med. 1998 Feb;4(2):232-4. doi: 10.1038/nm0298-232. Nat Med. 1998. PMID: 9461199

4

Bcl-2 antisense oligonucleotides (G3139) inhibit Merkel cell carcinoma growth in SCID mice.

Schlagbauer-Wadl H, Klosner G, Heere-Ress E, Waltering S, Moll I, Wolff K, Pehamberger H, Jansen B. Schlagbauer-Wadl H, et al. J Invest Dermatol. 2000 Apr;114(4):725-30. doi: 10.1046/j.1523-1747.2000.00937.x. J Invest Dermatol. 2000. PMID: 10733680 Free article.

5

Activated N-ras contributes to the chemoresistance of human melanoma in severe combined immunodeficiency (SCID) mice by blocking apoptosis.

Jansen B, Schlagbauer-Wadl H, Eichler HG, Wolff K, van Elsas A, Schrier PI, Pehamberger H. Jansen B, et al. Cancer Res. 1997 Feb 1;57(3):362-5. Cancer Res. 1997. PMID: 9012455

6

Expression of Bcl-2 family members in human melanocytes, in melanoma metastases and in melanoma cell lines.

Selzer E, Schlagbauer-Wadl H, Okamoto I, Pehamberger H, Pötter R, Jansen B. Selzer E, et al. Melanoma Res. 1998 Jun;8(3):197-203. doi: 10.1097/00008390-199806000-00001. Melanoma Res. 1998. PMID: 9664140

7

Influence of increased c-Myc expression on the growth characteristics of human melanoma.

Schlagbauer-Wadl H, Griffioen M, van Elsas A, Schrier PI, Pustelnik T, Eichler HG, Wolff K, Pehamberger H, Jansen B. Schlagbauer-Wadl H, et al. J Invest Dermatol. 1999 Mar;112(3):332-6. doi: 10.1046/j.1523-1747.1999.00506.x. J Invest Dermatol. 1999. PMID: 10084311 Free article.

8

Deletions of the region 17p11-13 in advanced melanoma revealed by cytogenetic analysis and fluorescence in situ hybridization.

Okamoto I, Pirc-Danoewinata H, Ackermann J, Drach J, Schlagbauer Wadl H, Jansen B, Wolff K, Pehamberger H, Marosi C. Okamoto I, et al. Br J Cancer. 1999 Jan;79(1):131-7. doi: 10.1038/sj.bjc.6690022. Br J Cancer. 1999. PMID: 10408704 Free PMC article.

9

Novel Ras antagonist blocks human melanoma growth.

Jansen B, Schlagbauer-Wadl H, Kahr H, Heere-Ress E, Mayer BX, Eichler H, Pehamberger H, Gana-Weisz M, Ben-David E, Kloog Y, Wolff K. Jansen B, et al. Proc Natl Acad Sci U S A. 1999 Nov 23;96(24):14019-24. doi: 10.1073/pnas.96.24.14019. Proc Natl Acad Sci U S A. 1999. PMID: 10570191 Free PMC article.

10

Farnesylthiosalicylic acid inhibits the growth of human Merkel cell carcinoma in SCID mice.

Jansen B, Heere-Ress E, Schlagbauer-Wadl H, Halaschek-Wiener J, Waltering S, Moll I, Pehamberger H, Marciano D, Kloog Y, Wolff K. Jansen B, et al. Among authors: schlagbauer wadl h. J Mol Med (Berl). 1999 Nov;77(11):792-7. doi: 10.1007/s001099900052. J Mol Med (Berl). 1999. PMID: 10619439

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

19 results

Search Page